These preclinically demonstrated anticancer effects also appear promising in light of the analgesic effects shown for MAGL inhibitors, which, according to a recent preclinical study, are also associated with complete inhibition of chemotherapy-induced neuropathy [29]. This evidence concerns the gene MGLL and neuropathy.